A
1.57
-0.07 (-4.27%)
| Previous Close | 1.64 |
| Open | 1.63 |
| Volume | 265,877 |
| Avg. Volume (3M) | 495,527 |
| Market Cap | 31,957,352 |
| Price / Book | 3.43 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -2.31 |
| Current Ratio (MRQ) | 3.59 |
| Operating Cash Flow (TTM) | -21.89 M |
| Levered Free Cash Flow (TTM) | -12.17 M |
| Return on Assets (TTM) | -138.27% |
| Return on Equity (TTM) | -3,159.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Annovis Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.45% |
| % Held by Institutions | 13.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Quest Partners Llc | 30 Sep 2024 | 46,002 |
| Sterling Investment Advisors, Ltd. | 31 Dec 2024 | 23,974 |
| 52 Weeks Range | ||
| Median | 17.00 (982.80%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 15 May 2025 | 17.00 (982.80%) | Buy | 1.69 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 May 2025 | Announcement | Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results |
| 29 Apr 2025 | Announcement | Annovis Bio Appoints Hui Liu as Director of Biostatistics |
| 27 Mar 2025 | Announcement | Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE |
| 25 Mar 2025 | Announcement | Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program |
| 21 Mar 2025 | Announcement | Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results |
| 11 Mar 2025 | Announcement | Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |